10-K: Quanterix Reports FY2024 Results, Announces Akoya Biosciences Acquisition

Quanterix's FY2024 results show revenue growth and strategic acquisitions aimed at expanding its presence in diagnostics and biomarker analysis.

Summary

• Quanterix Corporation reported its FY2024 financial results, showing a 12% increase in total revenue to $137.4 million compared to $122.4 million in 2023.
• Product revenue remained relatively flat at $79.7 million, with increased consumable sales offsetting decreased instrument sales.
• Service revenue increased by 28% to $51.2 million, driven by higher volumes and prices at the Accelerator Laboratory.
• The company's net loss was $38.5 million, compared to a net loss of $28.4 million in the previous year.
• Quanterix announced an agreement to acquire Akoya Biosciences, Inc., a life sciences technology company, expected to close in the second quarter of 2025.
• The company completed the acquisition of Emission, Inc. in January 2025 for an upfront payment of $10.0 million, with potential milestone payments up to $60.0 million.
• The company expects to launch Simoa ONE, a new instrument, by the end of 2025.
• The company is working to remediate material weaknesses in internal control over financial reporting.

Sentiment

Score: 6

Explanation: The document presents a mixed picture, with revenue growth offset by increased losses and ongoing internal control issues. The acquisitions and new product launches are positive, but the financial challenges and risks temper the overall outlook.

Positives

• Total revenue increased by 12% to $137.4 million in FY2024.
• Service revenue grew by 28% to $51.2 million, driven by the Accelerator Laboratory.
• Collaboration and license revenue increased by $3.1 million, or 223%.
• The company launched LucentAD Complete, a multi-marker algorithmic test for Alzheimers disease, in November 2024.
• The company received ISO 13485 certification for its operations in Billerica, Massachusetts.

Negatives

• The company's net loss was $38.5 million, compared to a net loss of $28.4 million in the previous year.
• Instrument sales decreased due to reduced demand.
• The company is working to remediate material weaknesses in internal control over financial reporting.

Risks

• The Akoya Biosciences acquisition is subject to conditions and may not be completed.
• The company may not realize the anticipated benefits of the Emission acquisition.
• The company faces competition in the life sciences research and diagnostic markets.
• The company relies on single contract manufacturers for its Simoa HD-X and SR-X instruments.
• The company relies on limited suppliers for some materials and components.
• The company may experience delays in launching Simoa ONE.
• The company may be subject to product recalls.
• The company may be subject to increased regulatory scrutiny.
• The company may be unable to protect its intellectual property.
• The company may be affected by changes in U.S. government policies, including tariffs and research funding.

Future Outlook

The company expects to launch Simoa ONE by the end of 2025 and anticipates continued growth in the diagnostics market.

Industry Context

The FDA approval of Leqembi and Kisunla as disease-modifying treatments for Alzheimers disease has underscored an urgent need for non-invasive widely available blood tests to facilitate diagnosis in the early stages of the disease to identify patients for treatment when therapeutic intervention is most likely to provide clinical benefit.

Related Party Transactions

• The company has related party transactions with Harvard University, Tufts University, and UltraDx Limited.

Stakeholder Impact

• The acquisition of Akoya Biosciences, Inc. is expected to benefit shareholders by creating a more comprehensive biomarker analysis platform.
• The launch of LucentAD Complete is expected to benefit patients with cognitive issues by providing a more accurate diagnostic tool for Alzheimers disease.

Next Steps

• Complete the acquisition of Akoya Biosciences, Inc.
• Launch Simoa ONE by the end of 2025.
• Continue to remediate material weaknesses in internal control over financial reporting.

Key Dates